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Glycans modify proteins required for regulation of immune
cells, and alterations have been associated with inﬂam-
matory conditions. For example, speciﬁc glycans regulate
T-cell activation, structures, and functions of immuno-
globulins; interactions between microbes and immune and
epithelial cells; and malignant transformation in the in-
testine and liver. We review the effects of protein glyco-
sylation in regulation of gastrointestinal and liver
functions, and how alterations in glycosylation serve as
diagnostic or prognostic factors, or as targets for therapy.Keywords: Glycan; Glycome; Glycomic; Glycosylation; IBD; Liver
Disease.
rotein glycosylation is a post-translational modiﬁ-Abbreviations used in this paper: AFP, a-fetoprotein; CRC, colorectal
cancer; FUT2, fucosyltransferase 2; FUT8, fucosyltransferase 8; GlcNAc,
N-acetylglucosamine; HCC, hepatocellular carcinoma; HCV, hepatitis C
virus; IBD, inﬂammatory bowel disease; Ig, immunoglobulin; IL, inter-
leukin; LC, liquid chromatography; MGAT, mannosyl (a-1,3-)-glycoprotein
b-1,2-N-acetylglucosaminyltransferase; NAFLD, nonalcoholic fatty liver
disease; NASH, nonalcoholic steatohepatitis; Th, T helper; UC, ulcerative
colitis.
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versity required for their interactions with other proteins
and cells. The diversity of the glycome (repertoire of glycans
structures in an organism) reﬂects their multiple functions
in cells, and glycans act as an interface between the cell
surface and the environment.1 Glycans regulate folding and
functions of proteins and lipids.2 The glycome is affected by
genetic and environmental factors, and changes have been
associated with development of inﬂammation. Disruption of
genes that encode speciﬁc glycosyltransferases causes al-
terations in the immune system that range from immune
suppression to autoreactivity,2–4 indicating the importance
of glycans in regulation of the immune response.
Glycans regulate the cellular and humoral immune re-
sponses,5 including assembly of peptide-loaded major his-
tocompatibility complexes antigens,6,7 reorganization of
T-cell receptor complexes,8 modulation of immune receptor
clustering, endocytosis, receptor signaling,9 and immuno-
globulin functions.10,11 Some glycan motifs serve as danger-
associated molecular patterns or pathogen-associated
molecular patterns.12 The immune system contains
different classes of glycan-binding proteins, including C-type
lectins, galectins, and siglecs, which are expressed by im-
mune cells and can be secreted. Glycan-binding proteinsregulate leukocyte trafﬁcking, pathogen recognition, im-
mune cell activation, and immunosuppression.13–17 Changes
in protein glycosylation are associated with the pathogen-
esis of diseases, including cancer, infections, and autoim-
mune diseases.2,4,18 These include gastrointestinal and liver
disease, such as inﬂammatory bowel diseases (IBDs),19 liver
ﬁbrosis20 and cirrhosis,21 nonalcoholic fatty liver disease
(NAFLD),22 gastric cancer,23 colorectal cancer,24,25 and he-
patocellular carcinoma.26
There are many challenges to diagnosis of IBDs and liver
diseases, and to predicting responses to treatment or out-
comes of patients. Despite recent advances in IBD therapy, a
high proportion of patients are refractory to treatment, and
half of patients with ulcerative colitis (UC) do not achieve
sustained remission.27 For example, despite the fact that
corticosteroids are effective in controlling acute ﬂares of
IBD, 20%–30% of patients have only a partial response and
16% do not respond to corticosteroids.28 It is a challenge to
select the best treatment for patients due to the lack of
reliable biomarkers of response or adverse events. Bio-
markers are also urgently needed to differentiate patients
with liver steatosis from those with nonalcoholic steatohe-
patitis (NASH).
Changes in protein glycosylation might be used as
diagnostic and prognostic markers, as well as targets of
therapy for chronic inﬂammatory gastrointestinal diseases.
We review how alterations in protein glycosylation affect
development of chronic inﬂammatory gastrointestinal and
liver diseases and the application of glycomic analysis to
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therapy and outcome.Glycosylation in T Cells
Glycans regulate T-cell development, activation,
signaling, differentiation, and proliferation, as well as
thymocyte selection.8,27,29–31 Alterations in these processes
can lead to autoimmune diseases and cancer.5,32 It is not
clear whether alterations in cell glycosylation proﬁles occur
as an early event (inducing) or late event (accelerating) in
intestinal inﬂammation. Intestinal T cells from patients with
IBD have glycome proﬁles that differ from those individuals
without IBD, characterized by decreased levels of branched
N-glycans19,30 and increased levels of core fucosylation (the
addition of a fucose residue to the core structure of N-linked
glycans with an a1,6 linkage).33 These changes increase T-
cell–mediated intestinal immune response.
T cells from inﬂamed colonic mucosa of patients with
active UC have reduced expression of the a-1,6-
mannosylglycoprotein 6-b-N-acetylglucosaminyltransferase
gene (MGAT5) or overexpression of the fucosyltransferase 8
gene (FUT8),30,33 compared with cells from patients without
UC. T cells from patients with IBD have a glycome proﬁle
that has been associated with a decreased threshold for
activation and increased signaling and inﬂammatory
response30,33 (Figure 1). However, it is not clear whether
changes in the glycoproﬁle of T cells are a cause or a
consequence of intestinal inﬂammation. The cytokines
interleukin (IL) 2 and IL7 alter expression of Golgi
branching enzymes that control N-glycosylation in T cells.11
An inﬂammatory environment would consequently inﬂu-
ence N-glycosylation in T cells to affect their function.
Studies of patients with immune-mediated diseases,
such as multiple sclerosis, have found that variants in genes,
including IL17RA, IL2RA, MGAT1, and CTLA-4, along with
environmental factors, such as sunlight or vitamin D3 and
metabolism, dysregulate Golgi N-glycosylation to promote
autoimmunity.34 This ﬁnding indicates that N-glycosylation
contributes, as an early event, to pathogenesis of inﬂam-
matory diseases. During colitis induction with dextran so-
dium sulfate (DSS), mice with the disruption of MGAT5 gene
develop more severe colitis, with earlier onset, than mice
without disruption of this gene, with increased responses of
T-helper (Th)1 and Th17 cells.30 Alternatively, FUT8
knockout mice develop a less-severe colitis than mice that
express wild-type FUT8, producing lower levels of Th1 and
Th2 cytokines.33 Mice that express human fucosyltransfer-
ase 2 (FUT2) from a transgene have defects in T-cell
development and develop spontaneous colitis.35 Alterations
in N-glycosylation therefore dysregulate the T-cell response
and contribute to development of colitis.
Researchers have studied mice without uridine
diphosphate–N-acetylglucosamine (GlcNAc): bGal b-1,3-
N-acetylglucosaminyltransferase 6 (core 3 b1,3-N-
acetylglucosaminyltransferase), an enzyme involved in
synthesis of core 3–derived O-glycans, and mice without
core 1 synthase, glycoprotein-N-acetylgalactosamine 3-b-
galactosyltransferase 1 (also called T-synthase). Core 3b1,3-N-acetylglucosaminyltransferase–deﬁcient mice have
colon-speciﬁc reductions in mucin 2, increased permeability
of the intestinal barrier, and are highly susceptible to
dextran sodium sulfate–induced colitis, developing severe
forms of the disease.36 Mice with intestinal epithelial cell-
speciﬁc deﬁciency of core 1-derived O-glycans developed
spontaneous colitis. Their colonic mucosa becomes inﬁl-
trated by tumor necrosis factor–producing myeloid cells, in
the absence of lymphocytes.37 The promoter region of the
MGAT3 gene has CpG methylation in CD3þ T cells from
colon tissues of patients with IBD compared with healthy
individuals.38 Genetic and epigenetic facts can therefore
dysregulate the glycosylation pathway, resulting in altered
glycan structures that control T-cell functions and might
contribute to IBD pathogenesis.Glycocalyx
Glycans cover, essentially, all cell surfaces, forming a
dense and complex coat of sugar-chains termed glycocalyx.
This glycocalyx mediates interactions between intestinal
cells and the microbiota. Little is known about the contri-
butions of glycans to the composition and function of the
intestinal microbiota, and how alterations affect intestinal
homeostasis and the mucosa immune response. Exposure of
intestinal microbes to glycans, either from diet or intestinal
cells, affects their composition and function. Intestinal mi-
crobes use glycans from dietary plants, animal-derived
cartilage and tissue, and human cells as sources of nutri-
ents and energy.39 Variations in the glycocalyx or ﬂuctua-
tions in the abundance of dietary glycans might lead to
dysbiosis and contribute to development of IBD, colon
cancer,40 NAFLD,41 alcoholic liver disease,42 or cirrhosis.43
Research is needed to clarify the relationship among cell
glycosylation, dysbiosis, intestinal inﬂammation, and asso-
ciated diseases.
Glycans from cells or the diet can place selective pres-
sures on speciﬁc species of bacteria, which can be classiﬁed
as generalist or specialists.39 Individuals lacking a functional
copy of FUT2 are known as nonsecretors and have alter-
ations in their intestinal microbiome and increased sus-
ceptibility to infection and inﬂammatory disease, such as
Crohn’s disease.44 The FUT2 genotype of nursing mothers
associated with decreased risk for diarrheal diseases in their
infants, and milk rich in a1,2-linked fucosyl moieties was
proposed to promote the growth of beneﬁcial microbiota
species like Biﬁdobacteria longum subsp Infantis.45 Single
nucleotide polymorphisms in FUT2 were associated with
increased risk of primary sclerosing cholangitis, which often
develops in patients with IBD, alterations to the micro-
biome, and susceptibility to infectious agents.46 Loss of
core-1– or core-3–derived O-glycans is associated with
susceptibility to colitis due to alterations in mucin glyco-
sylation, which increase intestinal epithelial permeability,
leading to bacteria accessibility and growth. Mice with loss
of core 1–derived O-glycans from intestinal epithelial cells
have alterations to the composition of their gut microbiota,
with an inverse shift in the abundance of the phyla Bac-
teroidetes and Firmicutes.47
Figure 1. Protein glyco-
sylation in development of
IBD. Genetic and environ-
mental factors affect pro-
tein glycosylation and its
effects on development of
inﬂammation. Decreases
in core 3–derived O-
glycans, increases in core
fucosylation, and re-
ductions in branched
complex N-glycan struc-
tures have been associ-
ated with development of
IBD, affecting interactions
between intestinal cells
and the microbiota and
increasing activation of T
cells. Alterations in glyco-
sylation proﬁles and their
associated alterations in
the intestinal microbiome
can promote inﬂammation
in the intestinal mucosa.
Alterations in IgG glyco-
mes in serum samples
have been associated with
changes in IgG effector
functions that lead to in-
testinal inﬂammation;
studies are needed to
determine how these pro-
cesses contribute to
carcinogenesis. Changes
in protein glycosylation
might be detected in
serum samples and used
as diagnostic or prog-
nostic factors.
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teroides spp can induce epithelial fucosylation,48 indicating
the symbiosis between intestinal cells and microbes.49
Variations in glycocalix composition along the gastroin-
testinal tract39,50,51 might support survival and growth of
subpopulations of bacteria, which degrade different types of
glycans, with potential pathologic implications. Changes in
intestinal fungi have also been associated with intestinal
inﬂammation and IBD.52,53 It will be interesting to explore
their relationships with glycans in the intestine.Glycosylation Alterations in
Inﬂammation-Associated
Gastrointestinal Cancer
Cancer cells undergo changes in glycosylation patterns18
that contribute to development and progression ofcolorectal cancer (CRC). Changes such as the carbohydrate
antigen CA 19-9 (sialyl Lewisa) or those expressed on car-
cinoembryonic antigen are used as biomarkers in diagnosis
of CRC and in monitoring its progression.25 The most widely
detected glycosylation alterations in colorectal tumors
include increased levels of b1,6-branching N-glycans; (poly-
)N-acetyllactosamine extensions of N-glycans; and sialyla-
tion. Alterations in O-glycans associated with CRC include
reductions in core 3 and 4 O-glycans and higher levels of
core 1 glycans, (sialyl) T-antigen and (sialyl) Tn-antigen.
Changes in glycosylation proﬁle of colon cancer cells have
been described and alter their activities to promote
tumorigenesis and metastases. Tumor-associated glycans
are recognized by glycan-binding proteins (galectins, siglecs,
and selectins) on immune cells, modulating the anti-tumor
immune response.24,54
Patients with IBD are at increased risk for CRC, which
accounts for 10%–15% of deaths in patients with IBD.55
Figure 2. Immune-modulatory properties of glycans in IBD. The complex branched N-glycans have immunosuppressive
functions in the intestinal mucosa. Administration of glycans to mice and ex vivo human intestinal T cells, either orally and/or
by enemas, alter the T cell–mediated immune response. Increases in b1,6-branching N-glycosylation in intestinal T cells in-
creases their threshold for activation and inhibits their production of inﬂammatory cytokines, such as tumor necrosis factor,
interferon-gamma, and IL17A. This branching N-glycosylation also inhibits T-cell receptor signaling, leading to control of
intestinal inﬂammation and delayed disease progression. Glycans are therefore promising immune-modulatory agents that
might be developed for treatment of IBD.
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genetic alterations than those observed in sporadic cancers,
with early p53 mutations and frequent chromosome insta-
bility and microsatellite instability. These genetic changes,
together with immune dysregulation, alterations to the
microbiome, and breaches in the epithelial barrier,
contribute to carcinogenesis.56–58 Curiously, some of the
alterations in the cellular glycosylation are similar in IBD
and in CRC,59 such as the increased expression of the
oncofetal Thomsen Friedenreich carbohydrate antigen
(galactose b1,3N-acetylgalactoseamine) in O-glycans from
mucins extracted from CRC and UC samples,60 and the
increased expression of sialyl Tn that was associated with
the risk for cancer development in IBD mucosa.61,62
Accordingly, mice models lacking core 1 and core 3–
derived mucin type O-glycans develop spontaneous colitis-
associated cancer.32,63
Overexpression of b1,6 branching N-glycosylation has
been associated with malignancy,64 cell invasiveness,18,65–67
and reduced survival times of patients with cancer68
(Figure 1). Aberrant expression of branched glycans canaffect regulation of immune response, although little is
known about its effects in patients with IBD-associated CRC.
Increasing levels of branching N-glycosylation in T cells
through metabolic supplementation with GlcNAc increased
their anti-inﬂammatory properties30 (Figure 2). Adminis-
tration of GlcNAc to pediatric patients with refractory IBD
increased the intestinal mucus lining and clinical remis-
sion.69 The dual effects of branched glycans as structures
that promote carcinogenesis and modify the immune
response indicate their possible involvement in develop-
ment of inﬂammation-associated cancer (SS Pinho et al,
unpublished data, September 2019). Further studies are
needed on the relationship between glycosylation alterations
and carcinogenesis in patients with IBD, including dysregu-
lation of the immune response and intestinal microbiome.
Glycosylation Alterations in Liver
Diseases
Core hyperfucosylation has been observed in serum and
liver tissues from patients with cirrhosis70 and NASH,71 it
Figure 3.Glycome
markers of HCC. AJCC,
American Joint Committee
on Cancer staging system;
ELISA, enzyme-linked
immunosorbent assay;
MALDI-QIT-TOF, matrix-
assisted laser desorption/
ionization, quadrupole ion
trap time of ﬂight; NA2,
galactosylated non-
fucosylated biantennary
glycan; NA3Fb, a1-3-
fucosylated triantennary
glycan; NA4FB, branching-
a1-3-fucosylated tetra-
antennary glycan;
NG1A2F, agalacto core,1-
6,fucosylated biantennary
glycan; TNM, tumor node
metastases.
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noma (HCC).72–76 There is evidence that increased fucosy-
lation occurs directly in the tumor.77 Genomic analysis of
HCC showed overexpression of the FUT8 gene, responsible
for core fucosylation, indicating that these glycan alterations
promote hepatocarcinogenis, making them biomarkers and
potential therapeutic targets.78 There is evidence that
altered expression of fucosyltransferase 1 and b-1,3-
galactosyltransferase 5 contribute to development of
HCC.79 High expression of these enzymes in HCC tissues was
associated with shorter survival times of patients.80
B3GALT5 mediates synthesis of a precursor of the SLea
antigen, which might contribute to HCC development and
metastasis.81
These ﬁndings have been conﬁrmed in clinical studies
(Figure 3). Analyses of serum samples from patients with
hepatitis B virus–related HCC using the GlycoHCCTest foundan increase in a1-3-fucosylated triantennary glycan (in-
volves the SLex epitope) and a decrease in bisecting core a-
1,6-fucosylated biantennary glycan, compared with serum
from patients without HCC (Figure 3).82 GlycoHCCTest
quantiﬁes a1-3-fucosylated triantennary glycan and bisect-
ing core a1-6-fucosylated biantennary glycan by capillary
electrophoresis. This test identiﬁed patients with HCC with
81% diagnostic accuracy, equal to that of the assay for a-
fetoprotein (AFP), and levels of the measured glycans
correlated with tumor stage.
Glycoblotting is a platform that integrates mass spec-
trometry for rapid and efﬁcient glycome proﬁling of tissues
or whole serum.83 Serum samples from patients with HCC
have increased multibranched glycans compared to in-
dividuals without HCC. Comparisons of serum samples from
patients with cirrhosis with vs without HCC using liquid
chromatography (LC) and electrospray ionization tandem
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proﬁle in patients with HCC characterized by end products
of the GnT-V pathway.84
An automated machine for glycoblotting, called the
SweetBlot, allows for quantitative proﬁling of up to 50
glycoforms in human serum. The Sweetblot technology was
used to analyze serum samples from 114 patients with HCC
and 105 individuals without.85 The ratio of a tri-sialylated
triantennary complex type glycan with fucose residue on a
bigalactosylated biantennary fucosylated glycan identiﬁed
patients with HCC with an area under the curve of 0.810.
These glycans showed similarities to those associated with
HCC by the GlycoHCCTest.82 Alterations in glcosylation of
speciﬁc liver-secreted serum proteins, such as hemopexin,86
paraoxonase 1 heteroplamon,87 and vitronectin88 have also
been associated with HCC.
Remarkably, the best glcosylation marker of HCC is
probably the oldest: AFP:L3, the fucosylated L3 fraction to
total AFP ratio. This a-6 core fucosylation is detectable using
Lens culinaris agglutinin lectin and the L culinaris agglutinin-
reactive fraction of AFP (AFP-L3). This test identiﬁes pa-
tients with HCC more accurately than measurement of
AFP.89 So changes in glycosylation associated with HCC
include increased activity of a1-6 fucosyltransferase in
serum, leading to formation of AFP-L3; increased GnT-III,
resulting in a bisecting GlcNAc (used to detect early-stage
HCC); and up-regulation of GnT-V, leading to increased
branching and formation of tetra-antennary glycans
(involved in metastasis).90 Most glycomic biomarkers detect
large liver tumors with high levels of sensitivity, but have
not been adequately tested for detection of small tumors.
Glycome analyses might also be used to predict patient
outcomes or response to therapy.91 The GlycoCirrhoTest,
which measures the abundance of bisecting GlcNAc residues
and triantenarry glycans on serum proteins, can identify
patients with cirrhosis and determine their risk for HCC.
This test identiﬁed patients at risk for HCC with a hazard
ratio of 12.1 (95% conﬁdence interval, 2.8–51.6) and pa-
tients with a low risk of HCC with a negative predictive
value of 97%.92 In patients with compensated cirrhosis,
higher levels of Wisteria ﬂoribunda agglutinin-reactive col-
ony-stimulating factor 1 receptor were associated with
rapid development of HCC.93 These tools might be used in
HCC screening. Pretreatment glycome proﬁles have been
associated with outcomes of treatment in patients with
HCC.94 Glycome alterations are therefore consistent and will
be useful in diagnosis of HCC and determining patient
prognoses.Clinical Effects
The glycosylation proﬁle of plasma immunoglobulin (Ig)
G has been associated with clinical features of IBD.95 In
human serum, there are multiple glycoforms of IgG, result-
ing from the diverse glycan structures at the IgG crystal-
lizable fragment (Fc) region. The Fc region of antibodies
interacts with Fc receptors (such as FcgRs) on immune cells
to activate signaling pathways and responses to antigens.The type of glycan attached to the Fc regions of IgGs de-
termines which type of receptor they bind: Fcs that bind to
activating FcgRs promote inﬂammatory responses and Fcs
that bind to inhibitory FcgRs activate anti-inﬂammatory
responses.
Patients with rheumatoid arthritis have loss of a termi-
nal galactose (agalactosylation) on total IgG that appears in
the circulation before disease onset.96–99 In support of this
observation, serum levels of agalactosyl IgGs are increased
in patients with Crohn’s disease and correlate with levels of
C-reactive protein, a marker of inﬂammation.100 The aga-
lactosyl fraction of the fucosylated IgG oligosaccharides
(G0F/G2F) was increased in serum samples from patients
with Crohn’s disease or UC vs controls and associated with
disease severity.101 In fact, the glycosylation proﬁles of IgG
differ between patients with UC and Crohn’s disease, with
differences in fucosylation, galactosylation, and bisection, in
association with disease severity.95,102 Therefore, there is
heterogeneity in glycosylation patterns of IgG glycome
among different groups of patients with IBD, with different
levels of severity and response to treatment. The serum
glycome might therefore be used in determining prognoses
of patients with IBD. Studies are needed to determine
whether changes in IgG glycome are a proxy of bowel
damage and level of immune dysregulation, and whether
they can be detected before disease development to identify
patients at risk or in diagnosis.
Serum antibodies against glycans can be detected and
used as markers of autoimmune and inﬂammatory disor-
ders. For example, anti-glycoprotein 2, anti-mannobioside
carbohydrate IgG, and anti-Saccharomyces cerevisiae
(recognizing an oligomannosidic epitope)103 are markers
used in early diagnosis of IBD (to distinguish UC from
Crohn’s disease) to determine disease activity and to predict
disease course (development of aggressive disease)104,105
(Figure 1). Interestingly, a higher proportion of non-
affected relatives of patients with Crohn’s disease test pos-
itive for anti-glycan antibodies than individuals with no
relatives with IBD.106 Most interestingly, anti-glycan anti-
bodies have been detected years before a diagnosis of
Crohn’s disease and are associated with complicated disease
before its onset.107 The serum glycome is therefore a valu-
able source of diagnostic and prognostic markers of in-
ﬂammatory disorders, including IBDs.
Changes in glycosylation patterns in the mucosa might
also be prognostic factors for patients with IBD.108 Patterns
of branched N-glycans in inﬂammatory inﬁltrate of the in-
testinal mucosa of patients with UC19 have been associated
with response to therapy. Levels of branched N-glycans in
colon biopsies collected when patients received a diagnosis
of UC correlated with response to standard therapy, iden-
tifying patients who did not respond to conventional ther-
apy with 75% speciﬁcity. Combined analysis of this
glycobiomarker and level of C-reactive protein increased in
the accuracy of identiﬁcation of patients who did not
respond to standard therapy.108 Variations in IgG glycosyl-
ation are also associated with resistance of intravenous Ig
treatment.109
Figure 4.Overview of serum glycomic changes in chronic liver disease. The development of liver ﬁbrosis is associated with
increased under-galactosylation of N-glycans. The establishment of cirrhosis is characterized by the increased appearance of
bisecting GlcNAc residues. The development of HCC is characterized by increased branching of glycans and increase branch
fucosylation. In patients with NAFLD, the appearance of NASH is characterized by the increased presence of under-
galactosylated glycans.
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Diseases
The optimization and control of N-glycan proﬁles are
important for the efﬁcacy of the antibodies.110 Glyco-
engineered Igs with increased sialylation of Fc had a 100-
fold increase in anti-inﬂammatory activity in a mouse
model of arthritis.111 Intestinal T cells isolated from patients
with UC and treated with GlcNAc had increases in branching
glycosylation and reduced proliferation, T-cell receptor
signaling, and Th1 and Th17 cell-mediated responses,
including decreased production of tumor necrosis factor,
interferon-gamma, and IL17A.
Oral and enema administration of GlcNAc to mice with
severe colitis (due to disruption of MGAT5) reduced the
severity and progression of colitis due to control in the in-
testinal immune response30 (Figure 2). The effects of
GlcNAc are being tested in a phase 2 trial of patients with
IBD. Nineteen years ago, oral GlcNAc was reported to pro-
mote mucus production in intestinal tissues of children with
severe treatment-resistant IBD; 8 of 12 children given
GlcNAc achieved clinical remission.69 Given the effects of
GlcNAc as an immunomodulatory agent30 and promoter of
epithelial barrier integrity,69 it is worth exploring in IBD
prevention and treatment (Figure 2). Overall, glycans could
be developed as low-cost, nontoxic, targeted therapies
(alone or in combination with other agents) for IBD.Diagnostic and Prognostic Markers of
Liver Disease
Aberrations in protein folding affect their functions in liver
cells.112 Sinusoidal cells and hepatocytes have surface re-
ceptors that are modiﬁed by glycans. Changes in glycosylationpatterns affect receptor concentration and distribution and
have been associated with liver diseases (cirrhosis and HCC).
Certain glycoproteins accumulate in the circulation of patients
with liver diseases.113 Liver disease is an attractive ﬁeld for
the study of the serum glycome becausemost N-glycans found
in whole serum are attached to serum proteins produced in
the liver21 and to a lesser extent to Igs,20,70,114 which are
produced by B cells. Alterations in serum glycan structures
have been reported in patients with liver
diseases20,22,90,92,114,115,116 (Figure 4). Some glycomic-based
markers have potential for clinical use (Figures 3, 5, and 6).Fibrosis and Cirrhosis
Fibrosis is associated with increased levels of under-
galactosylated IgGs.20,70,117 Proﬁles of protein N-glycans
were generated from patient serum samples using 8-
aminopyrene-1,3,6-trisulfonic acid-labeled (N-glycan)
proﬁling on a high-throughput DNA sequencer (DNA
sequencer-assisted ﬂuorophore-assisted capillary elec-
trophoresis).118,119 Serum samples from patients with
chronic hepatitis C virus (HCV)20 or hepatitis B virus
infection120,121 had gradual increases in proportions of
under-galactosylated core fucosylated glycans and a
decrease in the proportion of triantennary N-glycans was
observed. Other groups reported an increased core fuco-
sylation and the presence of bisecting GlcNAc residues
using matrix-assisted laser desorption/ionization, quad-
rupole ion trap time of ﬂight analysis.122 Glyco-
alterations, including fucosylation and desialylation, on
speciﬁc serum proteins are also present during ﬁbrosis
development like a1-acid glycoprotein.123 The Fast-Lec
Hepa, an automated immune assay that measures
ﬁbrosis-related alterations in glycosylation of serum
Figure 5. Glycome-based
markers of ﬁbrosis and
cirrhosis. As a comparator
Fibrosis-4 and FibroTest,
which are already used in
clinical practice, have
been included in the table.
All patients had histologic
grading of liver disease.
Symbols used in the struc-
tural formulas are: blue
square indicates b-linked N-
acetylglucosamine (GlcNAc);
yellow circle indicates b-
linked galactose, red tri-
angle indicates a/b-1,3/6-
linked fucose; green circle
indicates a/b-linked
mannose, purple rhom-
boid: (a-2,3/6 linked) N-
acetylneuraminic acid.
AGP, a1-acid glycopro-
tein; AUC, area under the
curve; DSA-FACE,
DNA sequencer-assisted
ﬂuorophore-assisted capil-
lary electrophoresis; FIB-4,
Fibrosis-4; HBV, hepatitis
B virus; MALFI-TOF, matrix
assisted laser desorption/
ionisation time-of-ﬂight
analyzer; NA2, galactosy-
lated non fucosylated
biantennary glycan;
NA2FB, bisecting core a1-
6-fucosylated biantennary
glycan; NA3, triantennary
glycan; NGA2F, core fuco-
sylated agalactosylated
biantennary glycan;
PON, paraoxonase 1
heteroplasmon.
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also called MAC-2-BP),124–126 shows an excellent corre-
lation with ﬁbrosis stage.
Glycosylation changes are markers of not only ﬁbrosis,
but of inﬂammatory processes, such as chronic HCVinfection, that lead to ﬁbrosis. Increased levels of MAC-2-BP
are attributed to increased hepatic stellate cell activation127
and decreased during treatment of HCV infection. In serum
samples from patients with biliary atresia, levels of MAC-2-
BP ﬂuctuate based on the presence of cholangitis of portal
Figure 6.Glycome-based
markers of NAFLD and
NASH. AUC, area under
the curve; DSA-FACE,
DNA sequencer-assisted
ﬂuorophore-assisted capil-
lary electrophoresis;
ELISA, enzyme-linked
immunosorbent assay;
MS, mass spectrometry;
NA2, galactosylated non
fucosylated biantennary
glycan; NGA2F, core
fucosylated agalactosy-
lated biantennary glycan.
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markers of inﬂammation rather than ﬁbrosis.
The GlycoFibroTest measures ratios of N-glycans in
serum of patients with chronic HCV infection and results
correlate with ﬁbrosis stage determined by histologic anal-
ysis. Signiﬁcant decreases in GlycoFibroTest results are
observed by 4 weeks after initiation of treatment with
direct-acting antiviral agents for HCV infection and persist
in patients with a sustained virologic response to treatment
(X Verhelst et al, unpublished data, March 2018).
Similar ﬁndings were observed in analyses of results
from Fast-lec Hepa test in patients with chronic HCV
infection.125 Furthermore, decreases in FIB-4,129 aspartate
aminotransferase-to-platelet ratio index,129 and FibroTest
scores,130 and in transient liver stiffness measurements131
(markers of ﬁbrosis) were reported at the end of treat-
ment of patients with chronic HCV infection. We ﬁnd it
surprising that ﬁbrosis can begin to resolve in the short
timeframe of the treatment period.
In addition to markers of ﬁbrosis and inﬂammation,
serum glycome signatures have been described in patients
with cirrhosis. The GlycoCirrhoTest21 measures proportions
of bisecting GlcNAc containing N-glycans and proportions of
triantennary N-glycans. Its results can distinguish patients
with compensated cirrhosis from patients with chronic liver
disease without cirrhosis with 79% sensitivity and 86%
speciﬁcity. This bisecting GlcNAc is the end product of GnT-
III,132 an enzyme that is overabundant in hepatocytes in
cirrhotic nodules.132–134 Serum samples from patients with
cirrhosis have increased levels of colony-stimulating factor1 receptor, which can be measured by an antibody-lectin
sandwich enzyme-linked immunosorbent assay.135
So can glycomic markers more accurately detect liver
ﬁbrosis and liver cirrhosis than other biomarkers? A
glycomic-based test for ﬁbrosis identiﬁes patients with
advanced ﬁbrosis (F3–F4) with a diagnostic accuracy of at
least 80%—comparable to that of other serum tests for
ﬁbrosis, such as FibroTest136 and Fibrosis-4137 test, which
are used in clinical practice. Furthermore, combined results
from the FibroTest and GlycoCirrhoTest had increased
performance compared with the single test for diagnosis of
cirrhosis.21Nonalcoholic Fatty Liver Disease and
Nonalcoholic Steatohepatitis
Markers are needed to distinguish NAFLD from NASH,138
which still requires liver biopsy analysis.139,140 DNA
sequencer-assisted ﬂuorophore-assisted capillary electro-
phoresis analysis of glycomic signatures of serum samples
was able to distinguish patients with NASH from patients
with NAFLD. This GlycoNASHTest is based on an increase of
a core fucosylated agalactosylated biantennary glycan and a
decrease of galactosylated nonfucosylated biantennary
glycan.22,141 Its diagnostic performance is comparable to
that of the assays to measure K18F, currently the best
available noninvasive assay for detection of NASH. Inter-
estingly, the value of the GlycoNashTest increased signiﬁ-
cantly according to the level of lobular inﬂammation but not
with ﬁbrosis stage. A highly simpliﬁed assay for endo-b-N-
104 Verhelst et al Gastroenterology Vol. 158, No. 1
REVIEW
S
AND
PERSPECTIVESacetylglucosaminidase from Streptococcus pyogenes (endoS)
has been developed.114 This should help advance this
biomarker toward clinical implementation.
The Sweetblot technique, an automated protocol for in-
tegrated glycoblotting and mass spectrometry, detects a
combination of 3 glycans in serum (2 core fucosylated and 1
nonfucosylated triantennary glycans) and can distinguish
patients with NASH from those with only steatosis (area
under the curve, 0.83).142 Levels of these glycans correlate
with levels of lobular inﬂammation, ballooning, and stea-
tosis. Serum samples from patients with NASH have in-
creases in fucosylated MAC-2-BP and fucosylated
haptoglobin compared to patients with simple stea-
tosis.71,143,144 The GlycoNashTest and assays that measure
fucosylated MAC-2-BP and FucHpt were superior to tests to
measure CK-18 in detection of NASH, using liver biopsy
analysis as the reference standard.22,71,143,145
Liver Transplantation
Liver transplantation is the best option for many pa-
tients with end-stage liver disease, and has excellent long-
term results.146 Decreasing donor organ quality increases
the risk of complications, including the occurrence of pri-
mary nonfunction, requiring urgent repeated trans-
plantation.147 Changes in glycosylation of proteins in
perfusate, the solution used to transport the donor organ to
the acceptor, detected shortly before transplantation were
associated with the development of primary nonfunction
after liver transplantation.116 These changes might be used
as biomarkers of nonfunctioning livers before trans-
plantation and prevent futile liver transplantations. In the
ﬁrst year after liver transplantation, serum protein glyco-
sylation patterns are independently associated with organ
survival (X Verhelst et al, unpublished data, September
2019).
Newer Developments in Glycome
Analysis
Reliable glycan proﬁling of complex mixtures requires
detection of a wide range of glycans with high levels of
sensitivity.148 Analyses must be transferrable to affordable
high-throughput systems that can operate in an automated
fashion in the routine clinical laboratory environment. Lec-
tin and antibody–lectin microarrays might be used in
proﬁling. Lectins are carbohydrate-binding proteins that
recognize motifs of oligosaccharide structure, such as a
monosaccharide, a certain linkage, combination of mono-
saccharides.149 Lectin arrays and lectin-based ﬂow cytom-
etry methods are useful for initial assessments of
differences in glycomes between samples, or to screen
surfaces of living cells. However, there is a need to design
sufﬁciently robust automated immunoassays. An example is
the fast-lec Hepa test for liver ﬁbrosis.125 One major
disadvantage is that it is straightforward to identify glycan
structural alterations based on lectin binding data. This
makes it difﬁcult to associate biochemical changes with
pathologies. Also, it is a challenge to produce recombinant
forms of many of the most useful lectins, so they requirepuriﬁcation from their natural source. This is a disadvantage
for manufacturing of diagnostic tests.
Direct glycan structure proﬁling tools, like mass spec-
trometry, are used extensively in glycome research because
they provide useful information with a detailed structure
analysis. However, mass spectrometry is less suitable for
routine clinical chemical analyses, due to its higher level of
complexity and cost vs available alternatives (LC and
capillary electrophoresis).150,151 Moreover, accurate quan-
tiﬁcation of glycans by mass spectrometry requires careful
operation and often involves chemical glycan derivatization,
which is difﬁcult to implement. LC analysis of ﬂuorophore-
labeled glycans has been developed and provides a robust
method with a wide dynamic range for glycan proﬁling.149
Several laboratories use this method for glycan proﬁling.
LC is difﬁcult to parallelize and can be time-consuming if
large series of samples need to be analyzed.152
This problem is overcome with capillary electrophoresis.
High-throughput analysis methods on multicapillary ana-
lyzers of various types have been developed to analyze the
N-glycome of serum and glycoprotein sample types
(perfusate of liver transplants, urine, and others).118,119
Sample preparation is performed in a single 96-well plate;
multicapillary instruments originally designed for DNA
analysis can analyze up top 96 samples simultaneously in
30 minutes. This technique is excellent for high-throughput
glycomic proﬁling. As with LC, to enable sensitive detection,
the glycans need to be derivatized with a ﬂuorophore
through simple chemistry.
For capillary electrophoresis analysis, methods have
been developed to enable glycan release from the protein
followed by this labeling, without any intermittent puriﬁ-
cations. This allows the researcher to start with a serum
sample and prepare it for capillary electrophoresis proﬁling
of the N-glycans on the proteins in serum simply by adding
reagents, followed by incubation, which can be fully auto-
mated. Furthermore, this analysis can be transferred to
capillary electrophoresis analyzers, which are already used
for serum protein proﬁling in most modern clinical chem-
istry laboratories, enabling straightforward implementation
in clinical practice. The Glyco Liver Proﬁle (Helena Bio-
sciences, Newcastle, UK) is the ﬁrst regulated clinical diag-
nostic test that has become available to routine clinical
chemistry laboratories and is based on this technology. The
Glyco Liver Proﬁle allows for analysis of several glycan
biomarkers used to analyze liver tissues—particularly the
GlycoCirrhoTest.21 Other tests for speciﬁc quantiﬁcation of
alterations in IgG glycosylation associated with chronic
inﬂammation are also under development based on this
platform.114
Future Directions
Glycans regulate protein and cell functions. Changes in
the glycome have been associated with many gastrointes-
tinal and hepatic diseases. Alterations in glycan structure
cause pathologic events that contribute to development of
disease, and these can be used as biomarkers for diagnosis
and prediction of disease progression and response to
therapy. Supplementation with glycans has been shown to
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mediated immune response in human IBDs.
Combining data generated by advanced glycomic and
glycoproteomic analyses (see the Human Glycome Project,
https://human-glycome.org/) with data on the human
genome, epigenome, microbiome, and immune proﬁles will
increase our understanding of how speciﬁc glycans induce
or modify gastrointestinal and liver disease phenotypes.
Applying these ﬁndings to longitudinal and prospective
clinical studies would allow us to generate glycan-based
markers for use in diagnosis and prognosis, as well as
identify targets for therapy. It will be important to incor-
porate glycome analyses into clinical studies and the ther-
apeutic decision-making process of gastrointestinal and
liver diseases.References
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